Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focusing on central nervous system (CNS) diseases, has announced its plans to host a conference call and webcast on August 7, 2024, at 4:30 PM ET. The event will discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Participants can join the call using US dial-in 1-800-717-1738 or international dial-in 1-646-307-1865, with conference code 39584. Alternatively, they can use the 'Call me™' technology for instant telephone access. A webcast replay will be available in the Investors section of Relmada's website after the event.

News Market Reaction

-5.83%

1 alert

-5.83% News Effect

On the day this news was published, RLMD declined 5.83%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Conference Call and Webcast Information:
Date: Wednesday, August 7, 2024 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Conference: 39584
Webcast Access: Click Here

The conference call utilizes the “Call me™” technology

• https://emportal.ink/3zo6zXz
• Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link, above, for instant telephone access to the event.
• Call me™ link will be made active 15 minutes prior to scheduled start time.
  

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

FAQ

When will Relmada Therapeutics (RLMD) report its Q2 2024 financial results?

Relmada Therapeutics (RLMD) will report its second quarter 2024 financial results on August 7, 2024, during a conference call and webcast scheduled for 4:30 PM ET.

How can investors access Relmada Therapeutics' (RLMD) Q2 2024 earnings call?

Investors can access Relmada Therapeutics' (RLMD) Q2 2024 earnings call by dialing 1-800-717-1738 (US) or 1-646-307-1865 (International), using conference code 39584, or by using the 'Call me™' technology for instant access.

Will there be a replay available for Relmada Therapeutics' (RLMD) Q2 2024 earnings call?

Yes, a replay of the webcast will be available in the Investors section of Relmada Therapeutics' (RLMD) website at https://www.relmada.com/investors/ir-calendar after the event.

What period will Relmada Therapeutics' (RLMD) upcoming financial results cover?

Relmada Therapeutics' (RLMD) upcoming financial results will cover the second quarter ended June 30, 2024.